Free Trial
CNSX:ATT

Abattis Bioceuticals (ATT) Stock Price, News & Analysis

About Abattis Bioceuticals Stock (CNSX:ATT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
1.42 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ATT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abattis Bioceuticals and its competitors with MarketBeat's FREE daily newsletter.

ATT Stock News Headlines

Abattis Bioceuticals Stock Price History
Abattis Bioceuticals Corp. (ATTBF)
Banks aren’t ready for this altcoin—are you?
Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly positioned to fill it…
Malaysian Bulk Carriers Bhd (MBCB)
See More Headlines

ATT Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Abattis Bioceuticals investors own include Aphria (APHA), Surna (SRNA), CannTrust (CTST), HEXO (HEXO), Canopy Growth (WEED), Aurora Cannabis (ACB) and Laird (LRD).

Industry, Sector and Symbol

Stock Exchange
CNSX
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
CNSX:ATT
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (CNSX:ATT) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners